Oral Session 3-10B CML: Clinical Study (2)

[OS3-10B-3] Lack of negative impact of BCR-ABL^INS35bp on the outcome of CML: an analysis from the New TARGET 1

Kazuhito Yamamoto¹, Naoto Takahashi², Junichiro Yuda³, Masahiro Kizaki⁴, Tatsuya Kawaguchi⁵, Ritsuro Suzuki⁶, Kazunori Ohnishi⁷, Tomoki Naoe⁸, Itaru Matsumura⁹ (1.Hematol. Cell Therapy, Aichi Cancer Ctr., Nagoya, Japan, 2.Hematol. Nephrol. Rheumatol., Akita Univ., Akita, Japan, 3.Hematol., National Cancer Ctr. Hosp. East, Kashiwa, Japan, 4.Hematol., Saitama Med. Ctr., Saitama Med. Univ., Saitama, Japan, 5.Med. Technol., Kumamoto Health Science Univ., Kumamoto, Japan, 6.Oncol. Hematol., Shimane Univ. Hosp., Izumo, Japan, 7.Japanese Red Cross Tokai-Hokuriku Block Blood Ctr., Seto, Japan, 8.NHO Nagoya Med. Ctr., Nagoya, Japan, 9.Hematol. Rheumatol., Kindai Univ. Osaka-Sayama, Japan)